Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

I've been paying for Mounjaro for more than a year, and have lost a fair bit of weight. Now it's available on the NHS, will I ...

Experts say NHS patients should be monitored for at least a year after treatment ends, with tailored support provided if ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard ...

Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...